Claritev adds Jennifer Main to board; ex-CMS COO and TARP CFO takes new Class II seat
Claritev Corp
Board expanded from 11 to 12 directors; Main appointed to the newly created Class II directorship effective October 15, 2026, and joins the Audit Committee.
Concurrently, Mr. Jason Kap ceased serving as a member of the Audit Committee; no other committee changes disclosed.
Main is CFO of RealMDai (dba Certuma) and Overture Life since March 2026; previously CFO and COO of Amalgam Rx from 2021 to 2026.
She was Chief Operating Officer of the Centers for Medicare & Medicaid Services from 2018 to 2021, overseeing Medicare, Medicaid and marketplace programs, and CFO of Treasury's $700 billion TARP.
Compensation follows the non-employee director policy in the March 20, 2026 proxy; she will enter the company's standard indemnification agreement. No related-party transactions disclosed.
Effective as of the Effective Date, the Board appointed Ms. Jennifer Main to fill the newly created directorship, to serve as a Class II director and a member of the Audit Committee.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Jennifer Main was appointed as Class II director at Claritev Corp.
Action
appointed
Role
Class II director
Exact text from the filing
Effective as of the Effective Date, the Board appointed Ms. Jennifer Main to fill the newly created directorship, to serve as a Class II director and a member of the Audit Committee.
This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.